CALQUENCE ® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial Read more
NMDP BioTherapies To Present Data at ISCT 2024 on the Stability of Infectious Disease Marker Analytes During Donor Qualification for Allogeneic Cell Therapies Read more
Alectinib shows promise in phase 3 ALINA trial for non-small cell lung cancer By Investing.com Read more